Rhythm pharma
Rhythm Pharma’s obesity drug shows positive results in two Phase 3 trials
August 8, 2019Research and Development Rhythm pharma, clinical trial, health, obesity, pharma
Rhythm Pharma’s obesity drug setmelanotide achieved positive results in two pivotal Phase 3 trials. In both studies, setmelanotide met its …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
The evidence bar impacting UK medical cannabis access
November 6, 2026
